Multiple Sclerosis, Relapsing-Remitting
Conditions
Brief summary
This study will test whether photobiomodulation therapy improves muscle endurance and decreases inflammation in persons with relapsing-remitting multiple sclerosis. We will also investigate mechanisms for any improvements.
Detailed description
Persons with multiple sclerosis (MS) MS commonly experience muscle weakness and fatigue which may contribute to the commonly reported symptomatic fatigue. Photobiomodulation therapy (PBMT) induced with light in the visible red to near infrared (VIS/NIR) region of the spectrum (600-1000 nm) can stimulate cytochrome c oxidase and improve mitochondrial function. PBMT is an emerging therapeutic modality for soft tissue injury, chronic inflammation, neurodegeneration , and retinal diseases. PBMT has also been used to enhance muscle endurance, strength and recovery in healthy adults. We propose that in persons with MS, PBMT will 1) enhance regional muscle endurance after acute treatment and 2) enhance functional endurance after extended treatment. We will also test to determine if improvements are due to central or peripheral neuromuscular or cardiovascular mechanisms. Final, we will explore if regional PBMT can result in systemic anti-inflammatory effects.
Interventions
OTHERPhotobiomodulation Therapy
Photobiomodulation therapy, a mix of red lights thought to improve mitochondrial function will be applied in and acute and chronic manner to test whether muscle fatigue improves in persons with MS.
OTHERPlacebo
Device with sham light source
Sponsors
University of Wisconsin, Milwaukee
Marquette University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Relapsing remitting MS, 2. Independent or ambulatory with minimal aid. 3. Must be able to move foot (ankle dorsiflexion) at least moderately forcibly against gravity (manual muscle test score 3-5) 4. Subjects must be able to walk for 6 minutes independently with no or minimal use of an assistive device.
Exclusion criteria
1. No noticeable left right ankle strength asymmetry 2. No exacerbations (MS attacks) or immunosuppressive therapy use within the previous 6 months 3. No concurrent infection or known cardiovascular disease including having a pacemaker; or other serious medical co-morbidity including metabolic, mitochondrial, autoimmune, diseases or other co-existing neurologic conditions. 4. Not involved in any clinical trial or other research that could confound results. 5. Must not be pregnant 6. Must not have an active diagnosis of cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Muscle Fatigue | up to 4 week photobiomodulation intervention, immediately after the intervention, and then 4 months after this extended treatment | Change in muscle fatigue or recovery after photobiomodulation therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Systemic Inflammation | up to 4 week photobiomodulation intervention, and then again at 4 months post-intervention | Change in pro- and anti-inflammatory cytokines. |
Countries
United States
Outcome results
None listed